Literature DB >> 9570364

Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma.

K S Kim1, Y I Lee.   

Abstract

The imprinted genes, H19 and insulin-like growth factor II (IGF2), have been demonstrated to be necessary for embryonal development in humans. Both genes are reciprocally imprinted, with expression of the maternal H19 and paternal IGF2 alleles, and are normally characterized by monoallelic expression. Recently, loss of imprinting of these genes producing biallelic expression has been observed in childhood tumors including Wilms' tumors (WT), embryonal rhabdomyosarcoma, and adulthood tumors such as lung cancer. To test the existence of loss of imprinting in hepatocellular carcinoma (HCC), we analyzed the status of imprinting of H19 and IGF2 genes in three independent tumors, three HCC and one hepatoblastoma cell lines using AluI and ApaI polymorphisms of these genes, respectively. In contrast to the previous report, all the cases except one tumor and one HCC cell line showed biallelic expression of both H19 and IGF2 genes. Unlike WT, loss of imprinting (LOI) of IGF2 in HCC was not linked to down-regulation of H19 expression, but rather associated with coexpression for H19 and IGF2. Thus, Hl9 and IGF2 expression can be uncoupled in tumors with LOI. The frequent biallelic expression of H19 and IGF2 in hepatocellular carcinoma might play a causal role in the epigenetic mechanism involved in tumor development and/or process.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9570364     DOI: 10.1016/s0304-3835(97)00264-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  25 in total

Review 1.  Genomic imprinting: implications for human disease.

Authors:  J G Falls; D J Pulford; A A Wylie; R L Jirtle
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

2.  Methylation status of c-fms oncogene in HCC and its relationship with clinical pathology.

Authors:  J Cui; D H Yang; X J Bi; Z R Fan
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells.

Authors:  Geoffrey Rezvani; Julian C K Lui; Kevin M Barnes; Jeffrey Baron
Journal:  Pediatr Res       Date:  2012-01       Impact factor: 3.756

Review 4.  Genomic imprinting and cancer.

Authors:  J A Joyce; P N Schofield
Journal:  Mol Pathol       Date:  1998-08

5.  Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation.

Authors:  Ning Ma; Fuyuan Li; Dan Li; Yang Hui; Xidi Wang; Yu Qiao; Yanfen Zhang; Ying Xiang; Jianying Zhou; Lingyun Zhou; Xiaofei Zheng; Xu Gao
Journal:  Mol Cell Biochem       Date:  2011-11-04       Impact factor: 3.396

6.  Downregulated long non-coding RNA TCONS_00068220 upregulates apoptosis in gastric cancer cells.

Authors:  Zhiwei Zhao; Junlai Xue; Yan Song; Tianyou Liu; Daxun Piao
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

7.  Analysis of long non-coding RNA (lncRNA) expression in hepatitis B patients.

Authors:  Sunde Yılmaz Susluer; Cagla Kayabasi; Besra Ozmen Yelken; Aycan Asik; Didem Celik; Tugce Balci Okcanoglu; Suheyla Serin Senger; Cigir Biray Avci; Sukran Kose; Cumhur Gunduz
Journal:  Bosn J Basic Med Sci       Date:  2018-05-20       Impact factor: 3.363

Review 8.  Genomic imprinting and chromatin insulation in Beckwith-Wiedemann syndrome.

Authors:  J M Greally
Journal:  Mol Biotechnol       Date:  1999-04       Impact factor: 2.695

9.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

10.  Prohibitin 1 Regulates the H19-Igf2 Axis and Proliferation in Hepatocytes.

Authors:  Komal Ramani; Nirmala Mavila; Kwang Suk Ko; José M Mato; Shelly C Lu
Journal:  J Biol Chem       Date:  2016-09-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.